XML 61 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Income (USD $)
In Thousands, except Per Share data, unless otherwise specified
 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Net sales $ 2,069,235 $ 2,073,529 $ 1,927,118
Cost of goods sold 915,097 895,640 835,630
Gross profit 1,154,138 1,177,889 1,091,488
Selling, general and administrative expense 682,898 696,294 635,213
Research and development expense 214,040 186,439 172,266
Income from operations 257,200 295,156 284,009
Interest expense 51,112 53,135 63,717
Foreign exchange losses, net 5,040 13,842 3,884
Other (income) expense, net (21,883) (7,583) (3,875)
Income before income taxes 222,931 235,762 220,283
Provision for income taxes (59,084) (57,739) (33,348)
Net income including noncontrolling interests 163,847 178,023 186,935
Net loss (income) attributable to noncontrolling interests (69) 200 (1,445)
Net income attributable to Bio-Rad $ 163,778 $ 178,223 $ 185,490
Basic earnings per share:      
Net income per share basic attributable to Bio-Rad $ 5.79 $ 6.36 $ 6.70
Weighted average common shares - basic 28,290 28,031 27,665
Diluted earnings per share:      
Net income per share diluted attributable to Bio-Rad $ 5.72 $ 6.26 $ 6.59
Weighted average common shares - diluted 28,642 28,468 28,151